J.P. Morgan analyst Andrea Faria Teixeira has maintained their bullish stance on KVUE stock, giving a Buy rating on September 5.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Andrea Faria Teixeira’s rating is based on a combination of factors including the recent legal developments surrounding Kenvue, Inc. Despite concerns over potential links between acetaminophen use during pregnancy and autism, the legal landscape appears favorable for Kenvue. The company and other defendants have successfully countered previous litigation claims, with a judge excluding the plaintiffs’ expert opinions, which reduces the risk of significant liability.
Furthermore, the FDA’s previous stance on the matter, which highlights the limitations and inconsistencies in existing studies, supports the current labeling of Tylenol products. This regulatory position, combined with the relatively small percentage of sales attributed to pregnant women using acetaminophen, suggests that the financial impact on Kenvue may be limited. These factors contribute to a positive outlook for the company’s stock, justifying the Buy rating from Andrea Faria Teixeira.
In another report released on September 5, Bank of America Securities also reiterated a Buy rating on the stock with a $25.00 price target.
KVUE’s price has also changed moderately for the past six months – from $23.040 to $18.620, which is a -19.18% drop .